We investigated whether monocyte CD14 receptor gene promoter polymorphisms were associated with the development and severity of pre-eclampsia. We genotyped the CD14 -260 C/T polymorphism in 36 preeclamptic patients and 52 healthy pregnant controls. A total of 30.6% and 69.4% of pre-eclamptic patients had the C and T alleles, respectively, and 48.0% and 52.0% of the controls, respectively. More pre-eclamptic patients were TT homozygotes compared with controls (50.0% versus 13.5%). In pre-eclamptic patients, the TT homozygotes exhibited a significantly higher mean systolic blood pressure compared with the non-TT homozygotes (173 ± 28 mmHg versus 153 ± 22 mmHg). We also noted a tendency towards increased proteinuria and placental abruption in the TT homozygotes compared with the non-TT homozygotes. We conclude that CD14 gene promoter polymorphisms appear to be a risk factor for pre-eclampsia. With further research, these findings might form the basis of a prognostic tool for pre-eclampsia.
Introduction
Pre-eclampsia is seen in up to 7% of all pregnancies. 1 Endothelial activation is known to be a key event in the disease process, but the exact aetiology of preeclampsia remains to be elucidated. Under physiological conditions, the maternal immune system is in continuous contact with low levels of fetal antigen (fetoplacental lipid or protein), derived from fetal tissues or the placenta. 2 This exposure results in a mild inflammatory response mediated by the innate immune systems. 3 Among the innate systems, the numbers and activated forms of monocytes (increased intracellular reactive oxygen species, and expression of surface CD14, CD11b, CD64 receptors) are increased, while the numbers and cytotoxicity of natural killer (NK) cells are reduced during pregnancy. 4 In the experimental pregnant rat model, low doses of endotoxin caused exaggerated responses not observed in the CD14 receptor gene polymorphism and pre-eclampsia normal non-pregnant controls; responses that were reminiscent of pre-eclampsia. 5 This result suggested that inflammation, particularly the activation of monocytes whose main function is to produce cytokines that activate the inflammatory response, may be a critical factor in the pathophysiology of pre-eclampsia. 6 It is likely that monocytes are responsible for the excessive maternal inflammatory response sometimes observed during pregnancy. Although monocyte activation has recently been a focus with regard to the pathophysiology of pre-eclampsia, 7, 8 the exact mechanisms underlying these changes have not been elucidated. Monocytes interact with antigens, including bacteria and cell wall components such as lipopolysaccharide (LPS) and fetal tissue, via cell surface molecules such as CD14. 9 As CD14 lacks a transmembrane signalling domain, CD14 and the antigen complex stimulate the Toll-like receptor-4 (TLR-4).
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TLR-4 initiates an innate immune cascade by facilitating the release of a variety of cytokines, including tumour necrosis factor-α (TNF-α), interleukin (IL)-1, IL-6, IL-8, IL-12, platelet-activating factor (PAF), and several other chemokines and eicosanoids. The CD14 receptor gene is located on chromosome 5, within a region that contains other genes encoding growth factors and receptors. 11 A polymorphism in the promoter region of the CD14 gene (single base change from C to T at position -260) has been shown to influence tissue-specific promoter activity. 12 We hypothesized that if pre-eclampsia is the result of an excessive maternal inflammatory response during pregnancy, mediated by monocytes, the sensitivity and susceptibility of individuals to inflammation would constitute a risk factor in the development of pre-eclampsia. To test this hypothesis, we examined the incidence of monocyte CD14 receptor gene promoter polymorphisms in pre-eclamptic patients and normal healthy pregnant control subjects. We aimed to determine whether CD14 gene promoter polymorphisms were associated with the development and severity of pre-eclampsia.
Patients and methods

PATIENT POPULATION
This study was performed between September 2003 and January 2005. Preeclamptic patients who had visited the delivery room at Ansan Hospital (Ansan City, South Korea) for evaluations of disease severity and labour induction were enrolled in the study. The diagnosis of pre-eclampsia was confirmed in cases in which urinary protein excretion was > 300 mg/24 h and blood pressure was > 140/90 mmHg on two occasions, having been checked at intervals of 6 h. 13 We excluded three women who were pregnant with twins and three women suffering from chronic hypertension. The control subjects were randomly selected from 680 full-term pregnant women who had been admitted to Ansan Hospital for repeat caesarean sections or for labour induction due to post-term carriage of an infant. At admission, all control subjects had normal blood pressure and no urinary protein excretion. Among the potential control subjects, four had ruptured membranes, two had another medical disease, and four exhibited obstetric problems (fetal growth restriction, oligohydramnios, etc.) and were excluded from this study. The review board of our institution approved the protocols for this study and we obtained informed written consent from patients or family members of all subjects. Blood samples were obtained within 12 h of admission and stored frozen on site at -80°C until analysis. CD14 receptor gene polymorphism and pre-eclampsia
GENOTYPING OF CD14 -260 C/T POLYMORPHISM
Genomic DNA was employed in the CD14 -260 C/T genotyping. Genomic DNA was extracted from peripheral leucocytes using a commercial kit in accordance with the manufacturer's instructions (Gene All™, General Biosystem, Seoul, South Korea). We also conducted polymerase chain reactions (PCR) according to previously published procedures. ). The oligonucleotide primers 5-TAAGGCACTGAGzGATCATCC-3 and 5-GGCTTCACACTT-GTGAACTC-3 were employed in the amplification of a promoter region of the CD14 receptor gene. PCR was run in 40 cycles consisting of an initial denaturation step at 94°C for 30 s, annealing at 60°C for 45 s, and elongation at 72°C for 1 min. This was followed by a final extension step at 72°C for 5 min. PCR was conducted using a Thermocycler (Applied Biosystems, Foster City, CA, USA). The 329 bp PCR products were digested for 4 h at 37°C with HaeIII in accordance with the manufacturer's recommendations (Takara Korea, Seoul, South Korea). The digests were then analysed on a 2% agarose gel and stained with ethidium bromide. The digestion of the PCR products revealed a 329 bp product for the T allele, and the C allele was identified by the production of two products (170 and 159 bp).
STATISTICAL ANALYSES
All statistical analyses were conducted with SAS software (v9.12; SAS Institute Inc., Cary, NC, USA). We employed χ 2 tests to compare allelic and genotype frequencies between the two groups. Student's t-test and Wilcoxon's rank sum test were used to compare the disease severity in the pre-eclampsia group. A P-value of < 0.05 was considered to be statistically significant.
Results
A total of 104 subjects were considered for inclusion in the study; 42 pre-eclamptic patients and 62 healthy control subjects. After exclusion of those subjects that were not considered suitable for the study, 36 preeclamptic patients and 52 control subjects were enrolled in the study. The demographic characteristics of the two groups of subjects are shown in Table 1 . There was no significant difference in the maternal age or parity between the two groups. The gestational age and birth weights were found to be lower in the pre-eclamptic patients than in the control group because of labour induction prior to full term due to pre-eclampsia. The frequencies of the C and T alleles in the CD14 receptor gene promoter were 30.6% and 69.4% in the pre-eclampsia group, respectively, compared with 48% and 52% in the control group, respectively (Table 2 ). Statistical analysis showed that the preeclampsia group demonstrated higher frequencies of the T allele compared with the control group (P = 0.0201). With regard to genotypes, the pre-eclampsia group contained four (11.1%) CC homozygotes, 18 (50%) TT homozygotes and 14 (38.9%) heterozygotes. In contrast, the control group contained five (9.6%) CC homozygotes, seven (13.5%) TT homozygotes and 40 (76.9%) heterozygotes. These results indicated that TT homozygotes occurred with significantly higher frequency in the pre-eclampsia group (P = 0.005).
We then compared markers of disease severity, including mean systolic and diastolic blood pressures, extent of proteinuria, and the presence of other obstetric complications (fetal growth restriction, placental abruption), in pre-eclamptic patients according to their JE Lim, T Kim, NW Lee et al. CD14 receptor gene polymorphism and pre-eclampsia CD14 promoter genotype (Table 3 ). In the TT homozygotes, we noted four (22.2%) cases of placental abruption with massive proteinuria and one case of intrauterine fetal death. All of the patients with placental abruption were TT homozygotes. The mean systolic blood pressure was significantly higher in the TT homozygotes compared with the non-TT homozygotes (P = 0.0448), and we observed a tendency toward increased proteinuria and placental abruption in the TT homozygote group, although the increases were not statistically significant.
Discussion
From an immunological point of view, there are two distinct components involved in the development of pre-eclampsia. 15 The first is a pregnancy-specific component, which has been referred to as the magnitude of stimulus. An example of this can be seen in the case of twins or an abnormally large placenta. The second is a maternal-specific component, which refers primarily to the extent of the maternal response. For example, genetic susceptibility can cause pre-eclampsia, as can certain differences in the constitution or In our study, we aimed to characterize the differences in the extent of the maternal response to similar pregnancy-associated stimuli and to delineate which genetic risk factors more readily affected the activation of monocytes. Therefore, we excluded twin pregnancies because the magnitude of stimulus is different from that associated with a singleton pregnancy. To homogenize the study population, we also excluded subjects who had ruptured membranes or who were in active labour, because these conditions may be related to inflammation. To the best of our knowledge, this study is the first to evaluate the correlation between polymorphisms in the monocyte CD14 receptor gene promoter and pre-eclampsia. We found that the -260 C→T polymorphism was present in more patients in the preeclampsia group than in the control group. All of the cases with severe pre-eclampsia (placental abruption, massive proteinuria, fetal death) in our study were TT homozygotes. The mean systolic blood pressure was significantly higher in the TT homozygotes compared with the non-TT homozygotes. TT homozygous human monocytes have been shown to synthesize sCD14 at a significantly higher rate than monocytes of other genotypes and they were also more responsive to LPS after in vitro stimulation. 16 Therefore, we concluded that increased CD14 receptor density (membrane-bound and soluble forms) and increased maternal responsiveness might, at least in part, explain our results in TT homozygote pre-eclamptic patients. Tumour necrosis factor-α levels might also explain our results, as the levels increase in pre-eclampsia, 17 but the aetiology of this increase remains unknown. Most previous studies have focused on TNF-α gene polymorphism to explain the elevation in TNF-α levels. 18 -20 We would like to suggest that the CD14 receptor gene polymorphism might be another mechanism involved in the increase in TNF-α levels, and that the subsequent increased TNF-α levels might lead to pre-eclampsia. Previously, polymorphism of the CD14 receptor gene has been studied principally in association with myocardial infarction, coronary heart disease and sepsis. According to Hubacek et al. , 21 the -260 C→T change affects the level of CD14 gene expression, and in TT homozygotes the increase in the density of CD14 receptors is permanent and appears to be determined genetically. 21 have shown that this polymorphism modulates the sensitivity of individuals to infection and is a risk factor for myocardial infarction. 21 In a similar study conducted in Japan, CD14 promoter gene polymorphism was also implicated as a risk factor for acute myocardial infarction. 22 This gene polymorphism also creates an imbalance in the immune response to sepsis and affects an individual's susceptibility to septic shock and death. 23 However, it is important to note that other studies have found no association between polymorphisms of the CD14 receptor gene promoter and myocardial infarction, stroke or tuberculosis. 24 -26 It is possible that racial characteristics may play a role in the variability seen between studies in that the genetic profile of an individual might be a crucial determinant of the extent to which this polymorphism affects them. Racial differences did not affect the results of our study because we examined a racially homogeneous population. In addition, the overall genotype distribution of our control group, which consisted of a lowrisk population, was similar to that of a previous Japanese study. 19 There have been no comparable studies about CD14 polymorphism in our country. Also, different incidences of disease, as well as different study populations, might be partly responsible for some of the conflicting results from different studies. This study had limited power because our study population was small and included a relatively small number of patients with severe pre-eclampsia. Our study does provide preliminary findings about the correlation between polymorphisms in the CD14 receptor gene promoter and the risk of pre-eclampsia, which warrants further investigation in a larger study. Our results suggest the possibility of using the CD14 receptor gene polymorphism as a prognostic tool for disease severity and outcome in pre-eclampsia. Furthermore, our results may indicate a new therapeutic target for treatment, such as the development of an anti-CD14 monoclonal antibody for cases of severe pre-eclampsia in TT homozygotes. Further study is required to investigate any correlation between the levels of soluble CD14 or TNF-α and the presence or absence of the CD14 polymorphisms in patients with pre-eclampsia.
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